As of December 15, 2025, FSD Pharma Inc (HUGE.CN) reports a ROE (Return on Equity) of -65.19%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of FSD Pharma Inc's ROE (Return on Equity)
Over recent years, FSD Pharma Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -65.19% |
| 2020-12-31 | -87.58% |
| 2019-12-31 | -105.48% |
| 2018-12-31 | -44.50% |
| 2017-12-31 | -28.39% |
This slight upward trend highlights how FSD Pharma Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing FSD Pharma Inc's ROE (Return on Equity) to Peers
To better understand FSD Pharma Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| FSD Pharma Inc (HUGE.CN) | -65.19% |
| Indiva Ltd (NDVA.V) | 1434.44% |
| Body and Mind Inc (BAMM.CN) | 204.64% |
| American Green Inc (ERBB) | 170.00% |
| Acerus Pharmaceuticals Corporation (ASP.TO) | 130.00% |
| Avivagen Inc (VIV.V) | 101.38% |
Compared to its competitors, FSD Pharma Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.